Showing 1 - 10 of 79
The outcome of two Canadian product class actions in 2020 signal hurdles claimants may face around the globe in 2021 in alleging adverse health effects in mass tort claims involving products for consumption such as medical cannabis, other pharmaceutical products and food.
This report examines the key features of the Directive of the European Parliament and of the European Council on representative actions for the protection of the collective interests of consumers and its wider impact on consumer-led litigation across Europe, including comparative insights into national class action mechanisms in the United Kingdom, Belgium, Denmark, France, Portugal, Spain and Ireland.
While 2020 was undoubtedly the year of the COVID-19 pandemic, 2021 is becoming the year of the vaccination. In this article, our industry experts consider the latest developments relating to the vaccine and provide an overview of its impact on various sectors.
On the surface, the London Market enters 2021 looking very different to its 2020 version. Underwriting rooms lay empty, offices unoccupied, pubs eerily quiet. But beyond the physical stillness, this world leading hub has not paused for breath. Digital systems and solutions have taken centre stage as the London Market has responded to a seismic shift in working patterns and insurance risks.
Despite welcome news of several viable vaccines in production, having been approved for emergency use globally, the race to develop protections against and treatments for COVID-19 is far from over. Alongside the approved vaccines, there are more than 250 potential vaccines at various stages of development. These vaccines will require worldwide roll out in order to contain and protect against the continued spread of COVID-19.
Advances in genomics are turbocharging the global response to the COVID-19 pandemic and continuing to redefine how we understand healthcare.
In early December 2020, the UK government announced with considerable fanfare its approval of Pfizer/BioNTech’s COVID-19 vaccine. Around 40 million doses were ordered, and the UK’s mass vaccination programme commenced in December 2020, with the US, Canada, Bahrain and Saudi Arabia close behind. On 30 December 2020, the Oxford AstraZeneca vaccine received UK approval with the first doses administered in early January.
Almost one year on from the first reported case of the novel coronavirus in the Wuhan province of China, pensioner Margaret Keenan and intensive care unit nurse Sandra Lindsay, have now received the first vaccines in the UK and US respectively.
Integrating new technology systems into large institutions is notoriously difficult even when it is carefully planned. So how has the rapid roll-out of telehealth during the pandemic altered the risk landscape?
In this Q&A, Jenny Yu, the Industry Practice Leader for Chemicals and Life Sciences in the UK at Marsh & McLennan shares her thoughts on the impact of COVID-19 on the life sciences sector.